Identifying key prognostic and predictive targets in breast cancer

Ongoing Research by the Callagy/Ingoldsby Group (Email: grace.callagy@nuigalway.ie )

• Breast cancer is a heterogeneous disease and patients with similar clinical and pathological features can respond differently to the same treatment and can have very different outcomes

• We investigate a range of novel biomarkers as potential prognostic and therapeutic targets in breast cancer.  In addition, we investigate the molecular events that underpin breast cancer progression through the evaluation of different stages of the disease from early precursor lesions to in situ tumours to invasive disease and metastasis

• We test molecular targets in paraffin-embedded tumors and validate our findings in a large series of primary breast tumours for which we have detailed pathological and clinical data. We use immunohistochemical and in situ techniques and tissue microarray platforms.

• Our work is done in close collaboration with the Department Pathology at GUH, utilising an extensive archive of formalin-fixed paraffin-embedded breast tumour samples

• Identification of biomarkers of complex molecular events will ultimately improve diagnosis of breast cancer and further the individualisation of treatment for breast cancer        

 

Lab Members

 Current Postgraduate students

Elaine Walsh (PhD Candidate, School of Medicine Scholarship)

Aliaa Shalaby (MD Candidate)

 

•For a list of Professor Grace Callagy’s recent publications, please click here: http://www.ncbi.nlm.nih.gov/pubmed/?term=callagy+g

•For a list of Dr. Helen Ingoldsby’s recent publications, please click here: http://www.ncbi.nlm.nih.gov/pubmed/?term=ingoldsby+h